Lyndsi Cress, DO
Family Medicine · Little River, SCNPI 1629480751
Payments from drug & device makers
Across 300 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$811
- AstraZeneca$465
- AbbVie$432
- Boehringer Ingelheim$373
- Amarin Pharma, Inc.$311
- GSK$288
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,05599%
- Education$481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $811 |
| AstraZeneca | 32 | $465 |
| AbbVie(2 entities) | 31 | $432 |
| Boehringer Ingelheim | 18 | $373 |
| Amarin Pharma, Inc. | 18 | $311 |
| GSK | 18 | $288 |
| Pfizer | 19 | $280 |
| Lilly USA, LLC | 18 | $230 |
| Amgen | 12 | $215 |
| Dexcom, Inc. | 6 | $187 |
| Novartis | 9 | $134 |
| Bayer | 7 | $116 |
| Johnson & Johnson | 8 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $113 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $111 |
| Exact Sciences | 6 | $106 |
| Averitas Pharma Inc. | 3 | $104 |
| Hologic Sales And Service, LLC | 4 | $78 |
| Abbott | 4 | $77 |
| Nevro Corp. | 2 | $51 |
| Alnylam Pharmaceuticals Inc. | 2 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Philips North America LLC | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Astellas Pharma US Inc | 3 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Mylan Specialty L.p. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $26 |
| Merck | 2 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$5,103 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 95 | $134,842 |
| EliquisApixaban | 168 | $133,711 |
| OzempicSemaglutide | 80 | $121,422 |
| JardianceEmpagliflozin | 83 | $91,322 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $83,770 |
| RybelsusSemaglutide | 53 | $58,724 |
| TrulicityDulaglutide | 60 | $57,976 |
| FarxigaDapagliflozin Propanediol | 59 | $44,988 |
| JanuviaSitagliptin Phosphate | 22 | $30,640 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $29,078 |
| LinzessLinaclotide | 21 | $18,071 |
| EntrestoSacubitril/Valsartan | 25 | $17,077 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $11,994 |
| Nurtec OdtRimegepant Sulfate | 11 | $11,210 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $10,757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $230 | $192,818155 claims |
| Novo NordiskOzempic, Rybelsus | $811 | $180,145133 claims |
| PfizerEliquis, Nurtec Odt, Paxlovid | $280 | $149,088191 claims |
| Boehringer IngelheimJardiance | $373 | $91,32283 claims |
| GSKTrelegy Ellipta | $288 | $83,77079 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $465 | $82,946131 claims |
| MerckJanuvia, Janumet Xr | $26 | $41,39839 claims |
| AbbVieLinzess, Synthroid | $432 | $20,64453 claims |
| NovartisEntresto | $134 | $17,07725 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $113 | $10,50713 claims |
| Astellas Pharma US IncMyrbetriq | $40 | $8,05118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Little River
- Stephen GrubbLittle River$3.4M
- Tom ChristensenLittle River$3.1M
- Darron MolterLittle River$36K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.